Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: Applied Materials (AMAT.US) Posts Solid Q4 Results, DRAM and Advanced Packaging to Drive Accelerated Growth by 2027
Goldman Sachs maintains its "Buy" rating on Applied Materials but lowers its 12-month target price from $670 to $580.
Piper Sandler lowers General Mills target price to $35
Major Crypto ETFs Bled $1.5 Billion While Wall Street Went Dip Shopping
"Big Short" Burry increases short positions on Nasdaq 100 and semiconductors, says Nvidia (NVDA.US) influence may enter a "new paradigm"
"The Big Short" Michael Burry has increased his bearish bets on the Nasdaq 100 Index and semiconductor stocks.
Crypto prices
More
